mutation in hemoglobin gene
Showing 1 - 25 of >10,000
Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)
Not yet recruiting
- Hematologic Malignancy
- +21 more
- Fludarabine
- +4 more
- (no location specified)
Feb 9, 2023
An Intervention to Increase Genetic Testing in Families Who May
Recruiting
- BRCA1 Mutation
- +21 more
- Intervention Arm At-risk Relative/ARR Contacts
- +5 more
-
Basking Ridge, New Jersey
- +7 more
Nov 22, 2022
Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)
Recruiting
- Her-2 Negative Breast Cancer
- HRR Gene Mutation
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023
Homologous Recombination Repair Pathway Gene Mutation Spectrum
Not yet recruiting
- Breast Cancer
- (no location specified)
Jun 4, 2023
Colorectal Carcinoma, Liver Metastases Trial in Shanghai (anatomical liver resection, nonanatomical liver resection)
Not yet recruiting
- Colorectal Carcinoma
- Liver Metastases
- anatomical liver resection
- nonanatomical liver resection
-
Shanghai, Shanghai, ChinaZhongshan hospital
May 21, 2023
The Prevelence of IVS 1-6 [HBB:c.92 +6 T-C] Gene Mutation in
Not yet recruiting
- Beta-Thalassemia
- ARMS
- (no location specified)
May 10, 2022
DDX41 Gene Mutation Trial in France (For each person (index case or related) included in this study:)
Not yet recruiting
- DDX41 Gene Mutation
- For each person (index case or related) included in this study:
-
Bordeaux, France
- +4 more
Aug 28, 2023
Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit
Not yet recruiting
- Helicobacter Pylori Infection
- +3 more
- Detection of fecal samples with diagnostic kit
- +2 more
- (no location specified)
Jun 5, 2022
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
The Prevelence of HBB c.93-21 G-A in ß Thalassemia Patients
Recruiting
- Beta-Thalassemia
- ARMS PCR
-
Assiut, EgyptFaculty of Medicine Assiut University
Jan 30, 2023
Biallelic RPE65 Mutation-associated Retinal Dystrophy Trial in Beijing (FT-001 Low Dose, FT-001 Mid Dose, FT-001 High Dose)
Recruiting
- Biallelic RPE65 Mutation-associated Retinal Dystrophy
- FT-001 Low Dose
- +2 more
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 11, 2023
Patients With a Constitutional Alteration of the PTEN Gene
Not yet recruiting
- PTEN Gene Mutation
- (no location specified)
Nov 17, 2022
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Sacramento (Niraparib, Niraparib Tosylate Monohydrate,
Recruiting
- ATM Gene Mutation
- +16 more
- Niraparib
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
TRPV4 Gene Mutation Trial
Not yet recruiting
- TRPV4 Gene Mutation
- (no location specified)
Jan 9, 2023
Leber Hereditary Optic Neuropathy (LHON) Trial (NFS-02 Injection)
Not yet recruiting
- Leber Hereditary Optic Neuropathy (LHON)
- NFS-02 Injection
- (no location specified)
Apr 6, 2023
Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation Trial in Baltimore (Recommendation for treatment with
Recruiting
- Metastatic Solid Tumor
- +4 more
- Recommendation for treatment with immunotherapy
-
Baltimore, MarylandJohns Hopkins University
Sep 8, 2022
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)
Not yet recruiting
- Metastatic Solid Tumor
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 12, 2023
Learn About Tests Looking forGene Mutation in Lung Cancer in
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- No Intervention
-
Beijing, ChinaDepartment of Pathology, National Cancer Center/National Clinica
Feb 24, 2023
Trial
Not yet recruiting
- Leber Hereditary Optic Neuropathy (LHON)
- NR082 Injection
- Injection needle
- (no location specified)
Jan 30, 2023
Sickle Cell Disease Trial in Boston (Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA
Recruiting
- Sickle Cell Disease
- Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
-
Los Angeles, California
- +8 more
Jan 10, 2023